2nd Quarter 2025 Results

2nd Quarter 2025 Sales

$23.7B Worldwide increased ▲ **5.8%**

Excluding the impact of translational currency
Stelara impacted results by ~(710) basis points
Worldwide increased ▲ **4.6%**[1]


Diluted earnings per share (EPS)

$2.29 Worldwide increased ▲ **18.7%**

Adjusted diluted earnings per share[1]

$2.77 Worldwide decreased ▼ **(1.8)%**





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine. Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways."

$15.2 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 4.9% or 3.8% operationally[2]. Stelara impacted results[2] by ~(1,170) basis points. Primary operational drivers:

DARZALEX (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
Tremfya (guselkumab)
CARVYKTI (ciltacabtagene autoleucel) Suspension for IV Infusion
CAPLYTA (lumateperone) capsules 42 mg
Erleada (apalutamide) 60 mg tablets 240 mg tablet
Simponi (golimumab)
Spravato (esketamine) CIII nasal spray
RYBREVANT (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE (lazertinib)

$8.5 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 7.3% or 6.1% operationally[2] Primary operational drivers:

- Shockwave
- Electrophysiology
- Abiomed
- Wound Closure
- Surgical Vision
- Biosurgery
- Contact Lenses

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on July 16, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx
[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
[2] Non-GAAP measure; excludes the impact of translational currency.
Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 16, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson&Johnson